Table 2.
Pre-transplantation clinical and immunological risk factors associated with allograft loss.
| Factor | No. of patients | Hazard ratio(s) (HR) | CI 95% | p |
|---|---|---|---|---|
| Donor age (per 1 year of increment) | 389 | 1.016 | 1.003–1.030 | 0.015 |
| Cold-ischemia time (per 1 h of increment) | 389 | 1.055 | 1.028–1.082 | <0.001 |
| Recipient age (per 1 year of increment) | 389 | 0.993 | 0.978–1.008 | 0.349 |
| Sex female | ||||
| No | 248 | 1.00 | ||
| Yes | 141 | 1.475 | 0.975–2.232 | 0.066 |
| Re-transplantation | ||||
| No | 332 | 1.00 | ||
| Yes | 57 | 2.259 | 1.407–3.626 | 0.001 |
| Time on waiting list (per 1 year of increment) | 389 | 1.025 | 0.987–1.064 | 0.200 |
| Human leukocyte antigen (HLA)-A, -B mismatches (per 1 mismatch of increment) | 389 | 1.143 | 0.927–1.409 | 0.211 |
| HLA-DR mismatches ≥1 | ||||
| No | 119 | 1.00 | ||
| Yes | 270 | 1.929 | 1.152–3.232 | 0.013 |
| Anti-calcineurin drugs | ||||
| Tacrolimus | 215 | 1.00 | ||
| Cyclosporine | 174 | 0.962 | 0.636–1.456 | 0.856 |
| Triple maintenance immunosuppressant therapy | 0.219 | |||
| Calcineurine inhibitor + MMF + Pred | 263 | 1.00 | – | |
| Calcineurine inhibitor + Aza + Pred | 104 | 1.133 | 0.720–1.785 | 0.589 |
| Calcineurine inhibitor + Rapamycin + Pred | 22 | 0.759 | 0.276–2.088 | 0.593 |
| Induction therapya | ||||
| No | 347 | 1.00 | ||
| Yes | 42 | 1.580 | 0.878–2.843 | 0.127 |
| cPRAb | 389 | 1.010 | 1.005–1.015 | <0.001 |
| Presence of DSA | ||||
| No | 297 | 1.00 | ||
| Yes | 92 | 2.009 | 1.306–3.091 | 0.002 |
| Presence of DSA and C1q-binding ability | ||||
| No-DSA | 297 | 1.00 | – | – |
| Non-C1q-binding DSA | 62 | 1.270 | 0.720–2.238 | 0.409 |
| C1q-binding DSA | 30 | 4.160 | 2.420–7.151 | <0.001 |
Univariate Cox analysis.
CI, confidence interval; MMF, mycophenolate mofetil, Pred, prednisone; Aza, azathioprine.
aInduction treatment consisted of thymoglobulin.
bCalculated panel reactive antibody (cPRA) value at time of transplantation, retrospectively calculated according to unacceptable antigens detected by SAB-panIgG assay using OPTN database.